Our Pricing

Understanding Wegovy Risks: Evidence-Based Safety Information for UK Patients

Understanding wegovy risks uk prescription weight loss treatment is essential before starting semaglutide therapy. At Cured Pharmacy, our UK-registered clinical team provides transparent, evidence-based information about Wegovy's safety profile, helping you make an informed decision about this MHRA-licensed weight loss medication.

Common Wegovy Side Effects: What UK Clinical Data Shows

Wegovy (semaglutide 2.4mg) has been extensively studied in the STEP clinical trial programme involving over 4,500 participants [1]. The most frequently reported side effects are gastrointestinal in nature, affecting approximately 44% of participants during dose escalation phases.

Nausea is the most common side effect, typically occurring in 20-44% of patients during the first 8-12 weeks of treatment [1]. This usually diminishes as your body adjusts to the medication. Other common gastrointestinal effects include diarrhoea (30%), constipation (24%), and vomiting (9-24%), with severity generally mild to moderate [2].

Most side effects occur during the dose escalation period and reduce significantly once patients reach their maintenance dose. In the STEP-1 trial, only 4.5% of participants discontinued treatment due to gastrointestinal side effects, compared to 0.8% in the placebo group [1].

Managing Common Wegovy Side Effects

Our clinical team at Cured Pharmacy recommends several strategies to minimise gastrointestinal side effects. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce nausea. Staying well-hydrated and increasing fibre intake gradually helps manage constipation.

The gradual dose escalation protocol—starting at 0.25mg weekly and increasing every four weeks—is specifically designed to improve tolerability. Your UK prescriber may adjust this schedule based on your individual response and tolerance.

Serious Wegovy Risks: Rare But Important Contraindications

Whilst serious adverse events with Wegovy are uncommon, certain medical conditions represent absolute contraindications. Wegovy must not be used if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [3].

In rodent studies, semaglutide caused thyroid C-cell tumours at clinically relevant exposures. Whilst no cases of MTC have been confirmed in human trials to date, the MHRA requires this as a boxed warning [3]. Your UK prescriber will screen for thyroid cancer risk factors during your clinical assessment.

Pancreatitis occurred in 0.2% of Wegovy-treated patients versus 0.1% of placebo patients in the STEP trials [1]. Symptoms include severe abdominal pain radiating to the back, nausea, and vomiting. If you experience these symptoms, discontinue Wegovy immediately and contact your healthcare provider.

Wegovy is contraindicated in pregnancy and should be discontinued at least two months before a planned pregnancy. The medication has not been studied in pregnant women, and weight loss during pregnancy may harm the developing foetus [3].

Wegovy and Diabetic Retinopathy: What the Evidence Shows

In the SUSTAIN-6 cardiovascular outcomes trial of semaglutide, an increased risk of diabetic retinopathy complications was observed in patients with pre-existing diabetic retinopathy [4]. This finding led to specific MHRA guidance for patients with diabetes.

The increased risk appeared related to the rapid improvement in blood glucose control rather than a direct drug effect. Patients with a history of diabetic retinopathy should be monitored closely when starting Wegovy, particularly if they have poorly controlled diabetes [4].

For weight loss patients without diabetes, this risk is not considered clinically relevant. However, your UK prescriber will assess your complete medical history, including any history of retinal disease, during your consultation.

Cardiovascular Safety Profile

The SELECT trial, published in 2023, demonstrated that semaglutide significantly reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease [5]. This finding supports Wegovy's cardiovascular safety in overweight and obese patients.

Heart rate increases of 1-4 beats per minute have been observed with semaglutide treatment, though this is not considered clinically significant for most patients [2]. Your prescriber will evaluate any pre-existing cardiovascular conditions during assessment.

Wegovy Drug Interactions and Medication Safety

Wegovy slows gastric emptying, which can affect the absorption of oral medications. This is particularly important for medications with narrow therapeutic windows or those requiring rapid absorption [3]. Your UK prescriber will review all current medications during your consultation.

Insulin and insulin secretagogues (such as sulphonylureas) may require dose adjustment when used alongside Wegovy to reduce the risk of hypoglycaemia. If you're taking diabetes medications, your prescriber will provide specific guidance on monitoring blood glucose levels [3].

Oral contraceptives may have reduced efficacy during the first four weeks after starting Wegovy or increasing the dose. Additional non-oral contraceptive methods should be used during this period if you're of childbearing potential [3].

Warfarin and other oral anticoagulants may require more frequent INR monitoring when starting Wegovy, as changes in dietary intake and body weight can affect anticoagulation control.

Wegovy Risks vs Benefits: Clinical Trial Safety Data

The STEP clinical programme provides comprehensive safety data from 4,567 participants treated with Wegovy for up to 68 weeks [1]. Overall adverse event rates were 89.1% in the Wegovy group versus 83.9% in the placebo group, with most events mild to moderate in severity.

Serious adverse events occurred in 9.8% of Wegovy-treated patients compared to 6.4% of placebo patients, though most were not considered related to the medication [1]. The most common serious adverse events included cholecystitis (gallbladder inflammation), which occurred in 0.6% of Wegovy patients.

Gallbladder-related disorders, including cholelithiasis (gallstones), occurred in 2.6% of Wegovy patients versus 1.2% of placebo patients [2]. This increased risk is associated with rapid weight loss rather than semaglutide specifically and is seen with all effective weight loss interventions.

Treatment discontinuation due to adverse events occurred in 7.0% of Wegovy patients versus 3.1% of placebo patients in the STEP-1 trial [1]. This discontinuation rate is comparable to or lower than other weight loss medications licensed in the UK.

Long-Term Safety Monitoring

The STEP-5 trial evaluated Wegovy safety over 104 weeks, demonstrating a consistent safety profile with no new safety signals emerging with longer treatment duration [6]. Gastrointestinal side effects decreased over time, whilst weight loss benefits were maintained.

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures ongoing safety monitoring through regular medication reviews. We recommend follow-up consultations every 12 weeks to assess treatment response and monitor for any emerging concerns.

Who Should Not Take Wegovy: Complete Contraindications List

Wegovy is contraindicated in several specific patient groups. You should not use Wegovy if you have hypersensitivity to semaglutide or any excipients, personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 [3].

Wegovy is not recommended for patients under 18 years of age, as safety and efficacy have not been established in paediatric populations. It should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment [3].

Patients with inflammatory bowel disease or diabetic gastroparesis should use Wegovy with caution, as the medication's effect on gastric emptying may exacerbate these conditions. Your UK prescriber will assess whether Wegovy is appropriate for your specific circumstances.

Severe renal impairment (eGFR <30 mL/min/1.73m²) requires careful consideration, as gastrointestinal side effects may lead to dehydration and worsening renal function. No dose adjustment is required for mild to moderate renal impairment [3].

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
3. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799
4. Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141
5. Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
6. Rubino, D. M., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. If you experience serious side effects, discontinue use and seek immediate medical attention.